{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:04Z","timestamp":1740108124506,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Durch Verbesserungen in der neonatologischen Versorgung von Fr\u00fchgeborenen und die Entwicklung neuer Behandlungsm\u00f6glichkeiten der Fr\u00fchgeborenenretinopathie (\u201eretinopathy of prematurity\u201c [ROP]) haben sich die Anforderungen an das ROP-Screening seit der Ver\u00f6ffentlichung der letzten\u00a0Fassung der deutschen Leitlinie zum ROP-Screening im Jahr 2008 ver\u00e4ndert. Auf Grundlage aktueller Studiendaten wurde die Leitlinie in 2020 grundlegend \u00fcberarbeitet und in einer aktualisierten Fassung ver\u00f6ffentlicht.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel<\/jats:title>\n                <jats:p>Dieser Artikel fasst die wichtigsten \u00c4nderungen in der neuen Leitlinie zusammen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die Altersgrenze f\u00fcr einen Screeningeinschluss wurde f\u00fcr Kinder ohne zus\u00e4tzliche Risikofaktoren auf ein Gestationsalter von unter 31\u00a0Wochen gesenkt. Die Mindestdauer f\u00fcr eine Sauerstoffsupplementation, die einen Einschluss in das Screening bei Fr\u00fchgeborenen erforderlich macht, wurde auf \u00fcber 5\u00a0Tage angehoben. Eine Behandlung bei ROP in Zone\u00a0II kann nun schon bei jedem Stadium\u00a03 mit Plus-Symptomatik unabh\u00e4ngig von der Anzahl der betroffenen Uhrzeiten erfolgen. F\u00fcr die Nachkontrollen nach Anti-VEGF\u00a0(\u201evascular endothelial growth factor\u201c)-Therapie wurden Kriterien zur Frequenz und Dauer definiert. Das verbindliche Dokument f\u00fcr diese und weitere neue Empfehlungen ist die Leitlinie selber.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerungen<\/jats:title>\n                <jats:p>Die Empfehlungen der Leitlinie erm\u00f6glichen eine zuverl\u00e4ssige Identifikation von Kindern mit ROP-Risiko f\u00fcr den Einschluss in das Screening und eine rechtzeitige Erkennung fortgeschrittener Krankheitsstadien f\u00fcr die Therapieeinleitung, um so Erblindung durch ROP zu verhindern.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-021-01393-6","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:51:17Z","timestamp":1620046277000},"page":"1240-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Screening auf Fr\u00fchgeborenenretinopathie\u00a0\u2013 die wichtigsten \u00c4nderungen in der neuen deutschen Leitlinie 2020","Screening for retinopathy of prematurity\u2014the most important changes in the new German guidelines 2020"],"prefix":"10.1007","volume":"118","author":[{"given":"Jeany Q.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-925X","authenticated-orcid":false,"given":"Tim U.","family":"Krohne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00347-018-0675-3","volume":"115","author":"PP Larsen","year":"2018","unstructured":"Larsen\u00a0PP, Br\u00fcnder\u00a0MC, Petrak\u00a0M et\u00a0al (2018) Screening for retinopathy of prematurity: trends over the past 5\u00a0years in two German university hospitals. Ophthalmologe 115:469\u2013475","journal-title":"Ophthalmologe"},{"key":"1393_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00347-018-0683-3","volume":"115","author":"TU Krohne","year":"2018","unstructured":"Krohne\u00a0TU (2018) Fr\u00fchgeborenenretinopathie: Aktuelle Entwicklungen in Therapie und Epidemiologie. Ophthalmologe 115:454\u2013455","journal-title":"Ophthalmologe"},{"key":"1393_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-2008-1027168","volume":"225","author":"C Jandeck","year":"2008","unstructured":"Jandeck\u00a0C, Kellner\u00a0U, Lorenz\u00a0B et al (2008) Leitlinie zur augen\u00e4rztlichen Screening-Untersuchung von Fr\u00fchgeborenen. Ophthalmologe 105:955\u2013963","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1393_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00347-011-2519-2","volume":"109","author":"TU Krohne","year":"2012","unstructured":"Krohne\u00a0TU, Stahl\u00a0A, Aisenbrey\u00a0S et al (2012) Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zum Einsatz von Bevacizuma in der Therapie der Fr\u00fchgeborenenretinopathie: Stand 20.12.2011. Ophthalmologe 109:197\u2013204. https:\/\/doi.org\/10.1007\/s00347-011-2519-2","journal-title":"Ophthalmologe"},{"key":"1393_CR5","doi-asserted-by":"publisher","unstructured":"Deutsche Ophthalmologische\u00a0Gesellschaft e. V. (DOG), Retinologische\u00a0Gesellschaft e. V. (RG), Berufsverband der Augen\u00e4rzte Deutschlands e. V. (BVA) (2020) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zur Anti-VEGF-Therapie der Fr\u00fchgeborenenretinopathie: Stand: 18.05.2020. Ophthalmologe 117:873\u2013885. https:\/\/doi.org\/10.1007\/s00347-020-01170-x","DOI":"10.1007\/s00347-020-01170-x"},{"key":"1393_CR6","doi-asserted-by":"publisher","unstructured":"Maier\u00a0RF, Hummler\u00a0H, Kellner\u00a0U et al (2021) Augen\u00e4rztliche Screening-Untersuchung bei Fr\u00fchgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr.\u00a0024\/010, M\u00e4rz 2020): Gemeinsame Empfehlung von Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rzte Deutschlands (BVA), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugend\u00e4rzte e.\u202fV. (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.\u202fV., Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI). Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-021-01353-0","DOI":"10.1007\/s00347-021-01353-0"},{"key":"1393_CR7","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1038\/eye.2008.128","volume":"23","author":"AR Wilkinson","year":"2009","unstructured":"Wilkinson\u00a0AR, Haines\u00a0L, Head\u00a0K et\u00a0al (2009) UK retinopathy of prematurity guideline. Eye 23:2137\u20132139","journal-title":"Eye"},{"key":"1393_CR8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/bjophthalmol-2013-303123","volume":"97","author":"AJ van Sorge","year":"2013","unstructured":"van Sorge\u00a0AJ, Schalij-Delfos\u00a0NE, Kerkhoff\u00a0FT et al (2013) Reduction in screening for retinopathy of prematurity through risk factor adjusted inclusion criteria. Br J Ophthalmol 97:1143\u20131147","journal-title":"Br J Ophthalmol"},{"key":"1393_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/pch\/21.2.101","volume":"21","author":"AL Jefferies","year":"2016","unstructured":"Jefferies\u00a0AL (2016) Retinopathy of prematurity: an update on screening and management. Paediatr Child Health 21:101\u2013108","journal-title":"Paediatr Child Health"},{"key":"1393_CR10","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/archophthalmol.2012.2357","volume":"130","author":"GE Holmstr\u00f6m","year":"2012","unstructured":"Holmstr\u00f6m\u00a0GE, Hellstr\u00f6m\u00a0A, Jakobsson\u00a0PG et\u00a0al (2012) Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. Arch Ophthalmol 130:1418\u20131424 (Chicago, Ill. : 1960)","journal-title":"Arch Ophthalmol"},{"key":"1393_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/bjophthalmol-2019-314874","volume":"104","author":"G Holmstr\u00f6m","year":"2020","unstructured":"Holmstr\u00f6m\u00a0G, Hellstr\u00f6m\u00a0A, Gr\u00e4nse\u00a0L et al (2020) New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register. Br J Ophthalmol 104:943\u2013949","journal-title":"Br J Ophthalmol"},{"key":"1393_CR12","doi-asserted-by":"publisher","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"WM Fierson","year":"2018","unstructured":"Fierson\u00a0WM (2018) American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 142:e20183061","journal-title":"Pediatrics"},{"key":"1393_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00347-018-0675-3","volume":"115","author":"PP Larsen","year":"2018","unstructured":"Larsen\u00a0PP, Br\u00fcnder\u00a0M\u2011C, Petrak\u00a0M et al (2018) Fr\u00fchgeborenenretinopathie-Screening: Trends \u00fcber die vergangenen 5\u00a0Jahre an zwei deutschen Universit\u00e4tskliniken. Ophthalmologe 115:469\u2013475","journal-title":"Ophthalmologe"},{"key":"1393_CR14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jpedsurg.2019.07.021","volume":"55","author":"PP Larsen","year":"2020","unstructured":"Larsen\u00a0PP, Kipfmueller\u00a0F, Holz\u00a0FG et\u00a0al (2020) Retinal findings in neonates with congenital diaphragmatic hernia and extracorporeal membrane oxygenation. J\u00a0Pediatr Surg 55:1292\u20131295","journal-title":"J Pediatr Surg"},{"key":"1393_CR15","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41372-019-0487-6","volume":"39","author":"S Gonski","year":"2019","unstructured":"Gonski\u00a0S, Hupp\u00a0SR, Cotten\u00a0CM et\u00a0al (2019) Risk of development of treated retinopathy of prematurity in very low birth weight infants. J\u00a0Perinatol 39:1562\u20131568","journal-title":"J Perinatol"},{"key":"1393_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"key":"1393_CR17","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"The Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"The Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694 (Chicago, Ill. : 1960)","journal-title":"Arch Ophthalmol"},{"key":"1393_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","volume":"19","author":"M Isaac","year":"2015","unstructured":"Isaac\u00a0M, Mireskandari\u00a0K, Tehrani\u00a0N (2015) Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J\u00a0Aapos 19:140\u2013144","journal-title":"J Aapos"},{"key":"1393_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner\u00a0HA, Geloneck\u00a0MM, Chuang\u00a0AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123:1845\u20131855","journal-title":"Ophthalmology"},{"key":"1393_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner\u00a0HA, Kennedy\u00a0KA, Chuang\u00a0AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"1393_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu\u00a0J, Blair\u00a0MP, Shapiro\u00a0MJ et\u00a0al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006 (Chicago, Ill. : 1960)","journal-title":"Arch Ophthalmol"},{"key":"1393_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","volume":"14","author":"SY Jang","year":"2010","unstructured":"Jang\u00a0SY, Choi\u00a0KS, Lee\u00a0SJ (2010) Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J\u00a0Aapos 14:457\u2013459","journal-title":"J Aapos"},{"key":"1393_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong\u00a0RK, Hubschman\u00a0S, Tsui\u00a0I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35:675\u2013680","journal-title":"Retina"},{"key":"1393_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl\u00a0A, Lepore\u00a0D, Fielder\u00a0A et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (Rainbow): an open-label randomised controlled trial. Lancet 394:1551\u20131559","journal-title":"Lancet"},{"key":"1393_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaapos.2014.03.011","volume":"18","author":"W Chen","year":"2014","unstructured":"Chen\u00a0W, Binenbaum\u00a0G, Karp\u00a0K et\u00a0al (2014) Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser. J\u00a0Aapos 18:402\u2013404","journal-title":"J Aapos"},{"issue":"6","key":"1393_CR26","first-page":"311","volume":"54","author":"TU Krohne","year":"2020","unstructured":"Krohne\u00a0TU, Stahl\u00a0A (2020) Neue Empfehlungen zu Screening und Therapie der Fr\u00fchgeborenenretinopathie \u2013 Die wichtigsten \u00c4nderungen. Augenarzt 54:311\u2013312","journal-title":"Augenarzt"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01393-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-021-01393-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01393-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:07:48Z","timestamp":1638788868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-021-01393-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s00347-021-01393-6","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"type":"print","value":"0941-293X"},{"type":"electronic","value":"1433-0423"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.Q.\u00a0Li gibt an, dass kein Interessenkonflikt besteht. B.\u00a0Lorenz weist auf folgende Beziehungen hin: Novartis.\u00a0U.\u00a0Kellner weist auf folgende Beziehungen hin: Bayer Vital, Heidelberg Engineering, Mylan, Novartis, Roche, Samsung. A.\u00a0Stahl weist auf folgende Beziehungen hin: Allergan, Bayer, Novartis, Roche. T.U.\u00a0Krohne weist auf folgende Beziehungen hin: Alimera Sciences, Allergan, Bayer, Heidelberg Engineering, Novartis, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}